Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gaudy, Elizabeth T. (University of Illinois, Urbana), and R. S. Wolfe. Ureidoglycolate synthetase of Streptococcus allantoicus. II. Properties of the enzyme and reaction equilibrium. J. Bacteriol. 90:1531-1536. 1965.-The properties of
ureidoglycolate
synthetase from Streptococcus allantoicus grown on allantoin were studied, by use of the purified enzyme preparation and crystalline sodium
ureidoglycolate
. Ureidoglycolate synthetase activity was maximal over the pH range of 8.4 to 8.8. No cofactors were required for the reaction. Enzyme activity was inhibited by p-chloromercuribenzoate at relatively high concentrations, by Hg(++) or Zn(++) ions, and to a lesser extent by several other metal cations. The maximal velocity for the purified
ureidoglycolate
synthetase, determined graphically from a Lineweaver-Burk plot, was 220 mumoles of glyoxylate formed per min per mg of protein. The substrate concentration required for half-maximal velocity was 3.3 x 10(-2)m. The equilibrium constant for the synthesis of
ureidoglycolate
was determined in a series of reaction mixtures covering a wide range of initial concentrations of reactants. The position of the equilibrium was not affected by a change in pH or by the presence of enzyme. The equilibrium constant for the reaction in the direction of synthesis was 7.6, corresponding to a negative free energy change of 1,230 cal per
mole
.
...
PMID:Ureidoglycolate synthetase of Streptococcus allantoicus. II. Properties of the enzyme and reaction equilibrium. 585 83